Vanda Pharmaceuticals Stock News

Conference Call and Webcast to Follow WASHINGTON , July 27, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2022 o

WASHINGTON , June 2, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Jefferies 2022 Global Healthcare Conference in New

I am quite impressed with Vanda Pharmaceuticals' investing thesis. Though it cooled off recently, Vanda is still positing significant revenues that I expect would leap to a higher level either next ye

Vanda (VNDA) delivered earnings and revenue surprises of -1,000% and 3.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Mihael H. Polymeropoulos – President & Chief Executive Officer Kevin Moran –

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Approval For AstraZeneca-Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer The�

Conference Call and Webcast to Follow WASHINGTON, April 28, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2022 on

Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Its drug for severe COVID-19 could be a smash hit, based on recent clinical trial findings.

Amid the biotech bear market, many fundamentally sound companies are trading at a fraction of their intrinsic value.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)’s traded shares stood at 0.47 million during the last session, with the company’s beta value hitting 0.52. At the close of trading, the stock’s price was $10.84, to imply a decrease of -1.45% or -$0.16 in intraday trading. The VNDA share’s 52-week high remains $21.86, putting it -101.66% down since that … After The Stock Fell -3.04% Over The Week, Is Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) Still A Buy? Read More »

Upgrades According to 86 Research, the prior rating for NetEase Inc (NASDAQ:NTES) was changed from Hold to Buy. For the fourth quarter, NetEase had an EPS of $1.56, compared to year-ago quarter EPS o

Daiwa Capital cut the price target on Tesla, Inc. (NASDAQ: TSLA) from $980 to $900. Tesla shares rose 1.3% to $811.13 in pre-market trading. Needham lowered Coinbase Global, Inc. (NASDAQ: COIN) pr

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (NASDAQ: ADGI) announced th